XML 46 R22.htm IDEA: XBRL DOCUMENT v3.3.1.900

Note 16 - Former Employee Severance Expense	12 Months Ended
	Dec. 31, 2015
Notes to Financial Statements
Former Employee Severance Expense [Text Block]	16. Former Employee Severance Expense On April 30, 2015, the Company entered into resignation agreements with the Company’s former Executive Vice President, Preclinical Development and former Vice President of Pharmaceutical Sciences. As part of these resignation agreements, the Company modified their stock option agreements to provide for continued vesting until June 30, 2015 and to extend the post-termination exercise period from 90 days to one year, resulting in a minimal amount of additional stock-based compensation expense. On June 19, 2015, the Company entered into a resignation agreement with the Company’s former Chief Scientific Officer. Costs associated with the resignation agreements, consisting primarily of severance-related charges, are reflected in the former employee severance expense section in the condensed consolidated statement of operations for the year ended December 31, 2015. $221,183 related to these charges was included in other accrued liabilities as of December 31, 2015.

X

- Definition

The entire disclosure for former employee severance expense.

+ References

No definition available.

+ Details

Name:	dffn_FormerEmployeeSeveranceExpenseTextBlock
Namespace Prefix:	dffn_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration